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Background: This study compared the preventive effects of ramosetron and ondansetron on postoperative nausea 
and vomiting (PONV) in highly susceptible patients undergoing abdominal hysterectomy.
Methods: In a prospective, randomized, double-blinded study, a total of 120 highly susceptible women (non-
smokers, those receiving opioid-based IV patient-controlled analgesia [PCA]) undergoing abdominal hysterectomy 
were included in the study. Patients were divided into 2 groups and each group received either 0.3 mg of ramosetron 
or 4 mg of ondansetron, IV. All patients received fentanyl-based IV PCA during the 48 h postoperative periods. The 
incidences of PONV and side effects of 5-HT3 antagonists (headache and dizziness) were assessed at 3 intervals (<2 h, 
2-24 h and 24-48 h) postoperatively.
Results: Patients in the ramosetron group showed a significantly higher ratio of complete response and lower 
incidence of nausea during the 24-48 h interval after surgery compared with those the ondansetron group. 
Conclusions: Ramosetron (0.3 mg) is more effective in preventing delayed PONV in highly susceptible women 
undergoing abdominal hysterectomy compared with ondansetron (4 mg).  (Korean J Anesthesiol 2011; 61: 488-492)
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Introduction
Postoperative nausea and vomiting (PONV) are common 
pro  blems after general anesthesia. Aside from the unpleasant 
ex  perience to the patient, PONV poses multiple potential 
medical risks. Increased intra-abdominal pressure and 
forceful vomiting jeopardize abdominal suture lines and may 
risk esophageal rupture. Elevated central venous pressures 
are known to increase morbidity after ocular, tympanic and 
intracranial procedures. In addition, the risk of aspirating gastric 
contents increases with PONV, especially if airway reflexes are 
impaired [1].
The etiology of PONV after general anesthesia is complex. 
Apfel et al. [2] reported that the female gender, prior history of 489 www.ekja.org
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motion sickness or PONV, non-smokers and the use of post  ope-
rative opioids were the most important predictors for PONV. If 
0, 1, 2, 3 or all of these risk factors were present, the incidence of 
PONV was 10%, 21%, 39%, 61% and 79%, respectively. Currently, 
5-hydroxytryptamine type 3 (5-HT3) receptor antagonists are 
widely administered to treat or prevent PONV. However, there 
are considerable differences in the pharmacokinetics and phar-
macodynamics among the drugs in this class.
In this study, we compared the preventive anti-emetic effi-
cacy for commonly used 5-HT3 antagonists, ramosetron and 
ondansetron, in highly susceptible patients (females, non-
smokers, those receiving postoperative opioids) undergoing 
abdominal hysterectomy. 
Materials and Methods
After obtaining approval by the Institutional Review Board 
at our hospital, written informed consent was obtained for this 
prospective double-blinded, randomized study of 120 healthy 
women with American Society of Anesthesiologists (ASA) physical 
status  classification I or II undergoing abdominal hysterectomy. 
There were no significant differences in the demographic data 
(Table 1). Additional inclusion criteria included patients aged 
18-60 years having PONV risk factors (i.e non-smokers, use 
of opioid-based PCA). Exclusion criteria included: history of 
allergies to any study medication, gastrointestinal disease, insulin 
dependent diabetes mellitus, administration of anti-emetics or 
steroids 24 h prior to surgery, active pregnancy, major cardiac 
or neurological disease and impaired hepatic/renal function.
Patients were randomly allocated to receive either ondanse-
tron (n = 60) or ramosetron (n = 60) by a computerized rando-
mi  zation table. All patients were premedicated with diaze-
pam (10 mg, PO) 1 h before surgery. Upon arrival to the OR, 
preoperative anxiety was evaluated using a 4 grade scale by an 
anesthesiologist blinded to the study groups. General anesthesia 
was induced with propofol (2 mg/kg) and vecuronium (0.1 
mg/kg) to facilitate intratracheal intubation. After successful 
intubation, anesthesia was maintained with 1.0-4.0 vol% 
sevoflurane and 50% nitrous oxide in oxygen. Ventilation was 
mechanically controlled and adjusted to maintain an end tidal 
concentration of CO2 between 35-40 mmHg and the body 
temperature was maintained at 36 ± 1
oC using an air mattress 
during surgery. Muscle relaxation was maintained with vecuro-
nium as needed. 
At 15 min prior to the end of surgery, patients received either 
ondansetron (4 mg) or ramosetron (0.3 mg) with fentanyl (50 
μg) and ketorolac (30 mg), IV (total volume 4 ml), in addition 
to being connected to a PCA. Injected drugs were prepared in 
identically shaped syringes by personnel not involved in the 
study. The PCA regimen consisted of 800 μg of fentanyl and 
180 mg of ketorolac total volume including saline, 100 ml and 
was programmed to a 2 ml/h basal infusion and 0.5 ml per 
demand with a 15 min lockout during a 48 h period. If patients 
complained of persistent nausea/or vomiting and wanted 
another rescue anti-emetics, metoclopramide was given. A 
visual analog score was used for postoperative pain evaluation. 
All episodes of PONV were recorded through direct questio-
ning by one anesthesiologist blinded to the study group or by 
complaints from patients during the 3 interval study periods 
within the first 48 h after anesthesia: 0-2 h, 2-24 h and 24-48 h. 
Complete response was defined as no PONV and no require-
ment for another rescue medication. Nausea was defined as a 
subjectively unpleasant sensation associated with awareness of 
the urge to vomit. The adverse effects of the 5-HT3 antagonists 
such as headache and dizziness were assessed during the study 
period. 
Statistical analyses were performed using a Chi-square test, 
Fisher exact test and unpaired t-test, as appropriate. A P < 0.05 
was considered significant. Values are expressed as means ± SD or 
number of patients (%). Power analysis was used to determine the 
number of patients in the study. Based on a preliminary study, 
a complete response during 48 h after surgery in a patients 
receiving ondansetron would be 70% and an improvement from 
70% to 90% was considered of clinical importance. Based on this 
assumption, a sample size of 60 in each group was calculated 
with an α-value of 0.05 and a power (1- β) of 0.8. 
Results
There were no significant differences in preoperative anxiety 
Table 1. Patient Demographics
Ramosetron  
(n = 60)
Ondansetron  
(n = 60)
Age (yr)
Height (cm)
Weight (kg)
Duration of anesthesia (min)
Input (ml)
Hx of PONV or motion sickness
Menstrual cycle
    0-6
    7-17
    >17
    Postmenopausal
Anxiety 
    None
    Mild
    Moderate
    Severe
45.0 ± 5.5
158.0 ± 4.9
58.3 ± 7.5
111.2 ± 44.2
1,261 ± 624.3
16
  0
28
29
  3
  1
45
14
  0
46.0 ± 6.8
156.7 ± 4.9
60.3 ± 7.9
121.0 ± 54.1
1,376.2 ± 615.6
12
  0
25
30
  5
  3
44
11
  2
Values are means ± SD or number of patients (%). PONV: post  ope-
ra  tive nausea and vomiting. There were no significant differences 
between the two groups.490 www.ekja.org
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(Table 1), postoperative pain (VAS) and side effects of the 5-HT3 
antagonists such as headache and dizziness (Table 2) between 
the 2 groups.
There were no significant differences in complete response, 
incidence of nausea/vomiting and rescue anti-emetic rescue 
during < 2 h and 2-24 h postoperatively. A complete response 
24-48 h after surgery was significantly higher in the ramosetron 
group (98.3%) compared with the ondansetron group (86.7%). 
The incidence of nausea 24-48 h after surgery was significantly 
lower in the ramosetron group (1.7%) compared with the 
ondan  setron group (13.3%). There was no difference in the 
use of rescue anti-emetics use during postoperative 24-48 h 
(ramosetron group, 0% and ondansetron group, 6.7%; Table 3).
Discussion
We compared the prophylactic anti-emetic efficacy of ramo-
setron and ondansetron in highly susceptible patients under-
going abdominal hysterectomy. A single injection of ramosetron 
(0.3 mg) was more effective than ondansetron (4 mg) in 
preventing PONV during the 24-48 h period after surgery.
The etiology of PONV after general anesthesia is complex, 
with the involvement of multiple patient, medical and surgery 
related factors. The risk factors include female gender, obesity, 
non-smokers, a history of motion sickness or PONV, menstru-
ation, type of surgical procedure, operation duration, anesthetic 
technique, postoperative pain and use of opioids [1,3]. From a 
neurophysiologic point of view, multiple emetic receptors in 
the chemoreceptor trigger zone, vestibular system, the cerebral 
cortex and visceral afferents from the gastrointestinal tract are 
involved in PONV [1,4]. The 5-HT3 receptor antagonists bind 
competitively to the 5-HT3 receptor in the chemoreceptor trigger 
zone and gastrointestinal tract to inhibit emetic symptoms [5]. 
Preoperative anxiety is known to be related with the increase 
of emesis. α-adrenergic activation by catecholamine release is 
thought to be related [6] and excessive air swallowing due to 
anxiety may also contribute.
Ondansetron was the first 5-HT3 receptor antagonist to 
become clinically available for the treatment and prevention 
of PONV. However, ondansetron is less selective for the 5-HT3 
receptor compared with the other 5-HT3 antagonists. It binds 
to 5HT1B, 5HT1C α-adrenergic and opioid receptors with low 
affinity [5]. Systematic review revealed that ondansetron’s 
prophylactic effect on vomiting is good, but the effect on pre-
venting nausea is less pronounced [7]. 
Ramosetron is a newly developed 5-HT3 receptor antagonist 
with a higher affinity and longer duration of action compared 
with other 5-HT3 receptor antagonists [8]. The elimination half-
life of ramosetron (9.3 h) is longer than that of ondansetron (3.5 
h), grainsetron (4.9 h) and alosetron (3.0 h) [5,8]. Ramosetron 
has a higher affinity (Ki = 0.091) and slower dissociation rate for 
5-HT3 receptors compared with other 5-HT3 receptor anta  go-
nists [9]. Also, the active metabolite M1 maintains high receptor 
occupancy and prolongs action duration [8]. Ayuhara et al. [10] 
reported that the occupancy of the 5-HT3 receptor correlated 
with the clinical efficacy of 5-HT3 receptor antagonists.
Multiple studies have reported that ramosetron has a greater 
or similar effect on prevention of PONV compared with other 
5-HT3 receptor antagonists. Ramosetron was more effective for 
preventing nausea and vomiting compared with ondansetron 
for spinal surgery [11], chemotherapy [12] and total knee replace-
ment surgery [13]. Also, ramosetron was more effective than 
granisetron in gynecologic surgery [14]. Hahm et al. [13] showed 
that ramosetron (0.3 mg) was more effective than ondansetron 
(4 mg) during the 2-48 h postoperative period following total 
knee replacement. However, in our study, there was a difference 
Table 2. Postoperative Pain Scores and Incidence of Side Effects
Ramosetron (n = 60) Ondansetron (n = 60)
VAS
    0-2 h
    2-24 h
    24-48 h
Headache 
    0-2 h
    2-24 h
    24-48 h
Dizziness
    0-2 h
    2-24 h
    24-48 h
8.4 ± 1.2
5.1 ± 1.6
2.6 ± 0.9
4 (6.7)
3 (5)
0
4 (6.7)
0
0
8.3 ± 1.1
5.1 ± 1.7
3.0 ± 1.4
4 (6.7)
4 (6.7)
0
5 (8.3)
0
0
Values are means ± SD or number of patients (%). VAS: visual analog 
score for pain evaluation. There are no significant differences between 
the two groups.
Table 3. Incidences of PONV and Complete Responses
Ramosetron  Ondansetron P value
N
<2 hr
    Complete response
    Nausea
    Vomiting
    Anti-emetics
2-24 hr
    Complete response
    Nausea
    Vomiting
    Anti-emetics
24-48 hr
    Complete response
    Nausea
    Vomiting
    Anti-emetics
60
47 (78.3) 
13 (21.6)
1 (1.7)
11 (18.3)
46 (76.7)
12 (20.0)
1 (1.7)
11 (18.3)
59 (98.3)
1 (1.7)
0 (0)
0 (0)
60
50 (83.3)
10 (16.7)
2 (3.3)
9 (15.0)
50 (83.3)
10 (16.7)
2 (3.3)
8 (13.3)
52 (86.7)
8 (13.3)
0 (0)
4 (6.7)
0.49
0.49
1.00
0.62
0.36
0.64
1.0
0.45
0.03*
0.03*
0.12
Values are number of patients (%) *Indicates P < 0.05 between the 
ramosetron and ondansetron groups.491 www.ekja.org
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of effectiveness only during the 24-48 h post-surgery period. 
Further, Hahm’s study showed a relatively higher incidence 
of nausea and lower complete response compared with our 
study although both studies targeted similar character patients 
(female, non-smoker, use of postoperative opioid use). Hahm’s 
study used spinal anesthesia and epidural hydromorphon 
PCA. Accordingly, patients showed a relatively higher complete 
response < 2 h after surgery (83-97%) and became lower (25-
50%) over time. Epidural opioids are associated with excellent 
pain relief but nausea and vomiting are frequent side effects. 
Eisenach et al. [15] reported an epidural morphine increased 
the incidence of nausea (50%) and requirement for anti-emetic 
treatment (30%) compared with intravenous PCA (the incidence 
of nausea, 30% and the requirement of treatment, 5%). But, 
because of an inadequate number of patients, they did not 
show the statistical significance. The emetic effects of epidural 
opioids are believed to be related to its rostral spread from the 
lumbar epidural site of injection to the CTZ (chemoreceptor 
trigger zone) and the vomiting centers. Hydrophilic agents such 
as morphine and hydromorphon have more rostral spread 
and higher incidence of nausea and vomiting compared with 
lipophilic agents such as fentanyl [1]. Different administration 
sites and physicochemical properties of opioids might partially 
explain the different results between Hahm’s and our study. 
Relatively low incidence of emetic sequelae in our study might 
mask the difference of effects between ondansetron and 
ramosetron. 
On the other hand, there were studies reporting similar 
effects [16,17]. Kim et al. [17] reported that ramosetron (0.3 
mg) and ondansetron (8 mg) did not show a the difference 
in the incidence and severity of PONV during the first 24 h 
after gynecological surgery. We did not find a difference in 
effect between drugs in the first 24 h. However, during the 
postoperative 24-48 h period, ramosetron was more effective 
than ondansetron. Considering that PCA is usually admini-
strated through the postoperative 48 h period, this finding is 
thought to have clinical significance. The incidence of PONV 
in Kim’s study (44-50%) was higher compared with our result 
(17-22%). Different from our study which was limited to 
abdominal hysterectomy, Kim’s study included laparoscopic 
procedures (48-52%). Gynecologic laparoscopic procedures 
have been known to induce emesis more frequently [1]. 
There are several limitations to our study. First, no control 
group was established. However, because all patients enrolled 
had several risk factors for PONV which included females, 
non-smokers, >1 h anesthetic duration, laparotomic surgery 
and postoperative opioid use, we estimated the incidence 
of PONV to be approximately 60-70% [2,18]. We thought it 
would be unethical not to administer any prophylactic anti-
emetics to establish a control group. A second limitation to 
our study concerns the dose of ondansetron and ramosetron. 
Currently, equipotent doses for ondansetron and ramosetron 
are unknown. Many clinical studies have compared ramosetron 
at 0.3 mg with ondansetron between 4-16 mg [11-13,16,17]. 
Previous pharmacokinetic studies used ramosetron at 0.3 mg 
and ondansetron at 4 mg [9,10]. Ondansetron is known not to 
have a linear dose response curve. In an animal study, the anti-
emetic effects increased until reaching 50 μg/kg but over that, 
there was a decrease until reaching 100 μg/kg where the effect 
was increased again with a 500 μg/kg dose [19]. In light of these 
findings, it is difficult to decide the optimal doses of ramosetron 
and ondansetron. Third, there are no established parameters to 
measure nausea severity. The incidence of nausea during 24-48 
h period is the important parameter with statistically significant 
differences in this study. Also, because nausea is a subjective 
symptom, it is difficult to accurately judge the development of 
nausea. A validated visual analog scale or a severity grade for 
nausea is needed to estimate the efficiency of 5-HT3 receptor 
antagonists. Lastly, we did not measure the doses of consumed 
fentanyl during the study periods. Opioid in PCA is a critical 
factor in developing delayed PONV. Accordingly, comparing 
opioid consumption for the exact evaluation of effect on 5-HT3 
receptor antagonists may be needed.
In conclusion, ramosetron at 0.3 mg is more effective in pre-
venting delayed PONV in highly susceptible women undergoing 
abdominal hysterectomy compared with ondansetron (4 mg). 
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